Inclusion Criteria:  Healthy male or non-pregnant female aged ≥18 years with a clinical diagnosis of facial rosacea; Provided IRB approved written informed consent; A CEA score of ≥3 prior to study drug application A PSA score of ≥3 prior to study drug application  Exclusion Criteria:  Female subjects who were pregnant, nursing, or had planned to become pregnant during study participation; History of hypersensitivity to the study product; Presence of ≥3 facial inflammatory lesions of rosacea; Particular forms of rosacea (rosacea conglobata, rosacea fulminans, isolated rhinophyma, and isolated pustulosis of the chin); Raynaud's syndrome, thromboangiitis obliterans, orthostatic hypotension, severe cardiovascular disease, cerebral or coronary insufficiency, renal or hepatic impairment, scleroderma, Sjögren's syndrome, or depression; Excessive facial hair (e.g., beards, sideburns, moustaches, etc.) that could interfere with diagnosis or study assessments; Presence of significant hypertension or circulatory disease